## AAPG: Ascentage Pharma Group Internat - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -7.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (52% of avg), momentum weakening (-5.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($27.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025**
- Source: GlobeNewswire | 20251201T080000 | Somewhat-Bullish | Relevance: 100%
- Ascentage Pharma will host a webcast on December 11, 2025, to discuss key data from the 67th American Society of Hematology (ASH) Annual Meeting. The management team, including Chairman & CEO Dr. Dajun Yang, will provide updates on the company's innovative portfolio and pipeline during both English and Chinese language sessions. The company focuses on developing differentiated therapies for cancer, with two approved products, Olverembatinib and Lisaftoclax, currently in registrational Phase III trials and commercialization in China.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $51 | $0 | 0% |
| 2025-11-10 | BTIG | $50 | $0 | 0% |
| 2025-11-05 | Piper Sandler | $48 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |
| 2025-11-10 | BTIG | init | Buy |
| 2025-11-05 | Piper Sandler | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 0.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- UBS Group AG: 0.0% (+149.4%)
- XY Capital Ltd: 0.0% (+224.1%)
- Point72 (DIFC) Ltd: 0.0% (-14.2%)
- Tema Etfs LLC       : 0.0% (-33.0%)
- ABC Arbitrage SA: 0.0% (+100.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 227% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.6B |
| Beta | 1.11 |
| 52W Range | $16.50 - $48.45 |
| Short Interest | 0.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -2.0% to -7.8% (-5.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.8pp (needs >4.0% for momentum thesis). AM_20 at -6.0% indicates price below own 20MA trend. Underperforming sector by 7.5pp, stock-specific weakness. Below SMA200 (0.96x), long-term trend not supportive. Volume at 52% of 20MA suggests lack of conviction. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.78% (CS: 3) | Weak |
| RSI_14 | 36.4 | Neutral |
| MACD Histogram | 0.08 | Bullish |
| vs SMA20 | 0.940x | Below |
| vs SMA50 | 0.875x | Below |
| vs SMA200 | 0.957x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $30.33
- **Stop Loss:** $27.95 (7.8% risk)
- **Target:** $32.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 399
- **Position Value:** $12,101.67
- **Portfolio %:** 12.10%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-03-26 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*